These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39365680)

  • 1. Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges.
    Soriano ER; Mysler E; Rios C; Xavier RM; Cardiel MH; Citera G
    Expert Opin Pharmacother; 2024 Oct; 25(15):2023-2033. PubMed ID: 39365680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of patients with rheumatoid arthritis in Latin America: a consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano De Estudio De Artritis Reumatoide.
    Massardo L; Suárez-Almazor ME; Cardiel MH; Nava A; Levy RA; Laurindo I; Soriano ER; Acevedo-Vázquez E; Millán A; Pineda-Villaseñor C; Galarza-Maldonado C; Caballero-Uribe CV; Espinosa-Morales R; Pons-Estel BA
    J Clin Rheumatol; 2009 Jun; 15(4):203-10. PubMed ID: 19502907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of rheumatology biologic registries in Latin America.
    de la Vega M; da Silveira de Carvalho HM; Ventura Ríos L; Goycochea Robles MV; Casado GC
    Rheumatol Int; 2013 Apr; 33(4):827-35. PubMed ID: 23263547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient's access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal.
    Laires PA; Mesquita R; Veloso L; Martins AP; Cernadas R; Fonseca JE
    BMC Musculoskelet Disord; 2013 Sep; 14():279. PubMed ID: 24067096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis.
    Osiri M; Dilokthornsakul P; Chokboonpium S; Suthipinijtham P; Koolvisoot A
    Adv Ther; 2021 Sep; 38(9):4885-4899. PubMed ID: 34370276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current therapies in rheumatoid arthritis: a Latin American perspective.
    Burgos-Vargas R; Catoggio LJ; Galarza-Maldonado C; Ostojich K; Cardiel MH
    Reumatol Clin; 2013; 9(2):106-12. PubMed ID: 23337169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
    Braun J; Kay J
    Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-TNF biologics and their biosimilars in rheumatoid arthritis.
    Mok TC; Mok CC
    Expert Opin Biol Ther; 2024 Jul; 24(7):599-613. PubMed ID: 38766765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to an optimal treatment. Current situation.
    Ugarte-Gil MF; Silvestre AM; Pons-Estel BA
    Clin Rheumatol; 2015 Mar; 34 Suppl 1(Suppl 1):S59-66. PubMed ID: 26188617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
    Woodworth TG; den Broeder AA
    Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.
    Lalor AF; Brooker JE; Rozbroj T; Whittle SL; Hill CL; Rowett D; Buchbinder R; O'Connor DA
    Semin Arthritis Rheum; 2022 Aug; 55():151988. PubMed ID: 35286905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
    Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
    JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
    Smolen JS; Landewé RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg JE; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2023 Jan; 82(1):3-18. PubMed ID: 36357155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects.
    Smolen JS; Caporali R; Doerner T; Fautrel B; Benedetti F; Pieper B; Jang M
    RMD Open; 2021 Jun; 7(2):. PubMed ID: 34099538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Education for patients with rheumatoid arthritis in Latin America and the Caribbean.
    Khoury V; Kourilovitch M; Massardo L
    Clin Rheumatol; 2015 Mar; 34 Suppl 1(Suppl 1):S45-9. PubMed ID: 26182886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
    Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
    J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis.
    Ascef BO; Almeida MO; de Medeiros Ribeiro AC; Andrade DCO; de Oliveira Júnior HA; Pereira TV; de Soárez PC
    Syst Rev; 2021 Jul; 10(1):205. PubMed ID: 34274019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
    Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
    Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in non-biological drugs for the treatment of rheumatoid arthritis.
    Venetsanopoulou AI; Voulgari PV; Drosos AA
    Expert Opin Pharmacother; 2024; 25(1):45-53. PubMed ID: 38126739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.